Events & Ideas

Durgin C, Huhn A, Bergeria C, Finan P, Campbell C, Antoine D, Dunn K. Inter-individual differences in sensitivity to opioids may explain different opioid risk profiles, but to date has only been evaluated in persons with opioid use disorder (OUD). This study examined individual differences in opioid effects within an opioid-naïve population. To be presented… Read More

Durgin C, Huhn A, Bergeria C, Finan P, Campbell C, Antoine D, Dunn K. Only a percentage of people exposed to opioids develop problematic use. Individual opioid sensitivity may explain different opioid risk profiles, but to date has only been evaluated in persons with opioid use disorder (OUD). This study examined how opioid sensitivity manifests… Read More

Moline ML, Cheng JY, Durgin C, Pype S, Buchhalter A, Henningfield J To identify differences and similarities in real-world abuse potential between dual orexin receptor antagonists (DORAs) and other drugs used as hypnotics, either Schedule IV (CIV) or unscheduled. DORAs, the newest hypnotic class, were placed in CIV based largely on human abuse potential (HAP)… Read More

Ashworth J, Davis VG, Mannion R, Hufford M   To be presented at the 85th CPDD Annual Scientific Meeting, Poster Session 2, June 19, 2023.

Lanier R, Schindler E, Kelmendi B, Bogenschutz M, Durgin C, Ashworth J Psilocybin and other psychedelics are currently being investigated for their potential to treat or assist in the treatment of a range of neurological and psychiatric conditions, including substance use disorders. These conditions have overlapping, but distinct pathophysiologies and treatment modalities. How, then, is… Read More

Moline ML, Cheng JY, Durgin C, Pype S, Buchhalter A, Henningfield J The two major hypnotic classes with distinct mechanisms of action, GABAergic drugs (benzodiazepines [BZs] and nonbenzodiazepines [i.e. zolpidem]) and dual orexin receptor antagonists (DORAs), are Schedule IV (CIV) drugs, but have notable differences in human abuse profiles. BZs are associated with drug tolerance/dependence,… Read More

To be presented at the 84th CPDD Annual Scientific Meeting, June 11-15, 2022.

Use of kratom, a botanical indigenous to Southeast Asia, has increased dramatically in the U.S. since 2006 with products proliferating rapidly. This is noteworthy, as kratom leaves contain bioactive alkaloids of which at least four act as partial, seemingly biased, agonists at mu opioid receptors and with activity at other neurotransmitter receptors. 

To be presented at the 84th CPDD Annual Scientific Meeting, June 11-15, 2022.

In a Phase 2 clinical trial REL-1017 showed rapid, robust, and sustained efficacy as adjunctive treatment for Major Depressive Disorder (MDD) without opioid-like side effects.